GEN17m
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
The Pharma Letter8h
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
bluebird bio Target of Unusually Large Options Trading (NASDAQ:BLUE)
Inc. (NASDAQ:BLUE – Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors purchased 1,893 put options on the stock. This is an increase of 28% compared to ...